Quantamental Technologies LLC Grows Stock Position in Celgene Co. (NASDAQ:CELG)

Quantamental Technologies LLC increased its stake in Celgene Co. (NASDAQ:CELG) by 949.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,530 shares of the biopharmaceutical company’s stock after purchasing an additional 13,146 shares during the quarter. Celgene makes up approximately 0.5% of Quantamental Technologies LLC’s investment portfolio, making the stock its 10th biggest position. Quantamental Technologies LLC’s holdings in Celgene were worth $1,343,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the stock. Numen Capital LLP raised its holdings in Celgene by 233.0% during the second quarter. Numen Capital LLP now owns 485,900 shares of the biopharmaceutical company’s stock valued at $44,938,000 after acquiring an additional 340,000 shares during the period. Fosun International Ltd bought a new stake in Celgene during the second quarter valued at about $2,032,000. Fort Washington Investment Advisors Inc. OH raised its holdings in Celgene by 1.8% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 28,122 shares of the biopharmaceutical company’s stock valued at $2,599,000 after acquiring an additional 485 shares during the period. Korea Investment CORP raised its holdings in Celgene by 1.9% during the second quarter. Korea Investment CORP now owns 837,851 shares of the biopharmaceutical company’s stock valued at $77,451,000 after acquiring an additional 15,500 shares during the period. Finally, Beddow Capital Management Inc. bought a new stake in Celgene during the second quarter valued at about $252,000. 74.04% of the stock is currently owned by institutional investors.

A number of equities research analysts have commented on the company. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 3rd. Barclays cut Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target on the stock. in a report on Friday, May 3rd. Mizuho cut Celgene from a “buy” rating to a “neutral” rating and decreased their price target for the company from $103.00 to $100.00 in a report on Monday, August 19th. ValuEngine cut Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Finally, Cowen reissued a “hold” rating and set a $102.00 price target on shares of Celgene in a report on Tuesday, July 30th. Two equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and three have given a buy rating to the company’s stock. Celgene has an average rating of “Hold” and a consensus target price of $94.60.

Shares of Celgene stock traded down $1.72 during trading on Friday, reaching $93.99. 3,566,143 shares of the stock traded hands, compared to its average volume of 3,395,367. The company has a market capitalization of $67.83 billion, a price-to-earnings ratio of 12.35, a P/E/G ratio of 0.45 and a beta of 1.46. The business has a fifty day simple moving average of $93.09 and a two-hundred day simple moving average of $92.67. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.44 and a quick ratio of 3.32. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $98.97.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.17. The company had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.22 billion. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The firm’s revenue was up 15.4% on a year-over-year basis. During the same quarter last year, the business posted $2.16 earnings per share. On average, research analysts predict that Celgene Co. will post 9.96 earnings per share for the current fiscal year.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.